Bascom Palmer Eye Institute invites you to join us in February 2017 for our fourteenth annual angiogenesis meeting. This unique and exciting symposium entitled *Angiogenesis, Exudation, and Degeneration 2017* will be held February 11, 2017 at the Mandarin Oriental Hotel in Miami, Florida. The meeting will feature an exceptional gathering of basic scientists, clinicians, and healthcare experts, all focused on understanding and treating neovascular and exudative diseases of the eye. The meeting will highlight the revolutionary pharmacotherapies now in development and clinical practice for the management of neovascular AMD, macular edema, diabetic retinopathy, and retinopathy of prematurity with a special emphasis on the present and future financial impact of these drugs on clinical practices and Medicare.
COURSE DESCRIPTION

Angiogenesis 2017 follows the tradition of excellence established by the widely acclaimed Angiogenesis programs between 2004 and 2016. Designed for retinal specialists, general ophthalmologists and researchers, the current program will review the latest therapies for exudative eye diseases and the use of these new treatments in clinical practice. We will emphasize current and future treatments for a broad spectrum of retinal diseases with special emphasis on age-related macular degeneration and diabetic retinopathy.

COURSE OBJECTIVES

Upon completion of this program, participants should be able to:

- Enhance patient care by evaluating the current global use of anti-VEGF drugs for exudative ocular diseases
- Manage patients with anti-VEGF therapy through the preferred dosing practices
- Improve management skills by evaluating all the risks associated with injections of an anti-VEGF drugs
- Analyze the rationale for emerging treatments for different macular and retinal degenerative conditions
- Analyze results of clinical trials in exudative and non-exudative macular diseases and apply to clinical practice
- Evaluate the benefits and limitations of combination therapies for exudative macular diseases
- Evaluate the benefits and limitations of different imaging strategies for macular diseases
- Understand the emerging imaging technology known as OCT angiography
- Enhance patient care by analyzing the genetic basis for different macular and retinal degenerative conditions
7:00 am  Registration and Continental Breakfast
7:55  Welcome and Overview
Philip J. Rosenfeld, MD, PhD; Harry W. Flynn, Jr., MD; and Carmen A. Puliafito, MD, MBA

SESSION I: Age-Related Macular Degeneration
Moderator: Philip J. Rosenfeld, MD, PhD

8:00  Genetics and Nutrition in AMD
Emily Y. Chew, MD
8:10  The Oil Spill Strategies for AMD: Update and Model System
Christine A. Curcio, PhD, FARVO
8:20  Cuticular Drusen: New Clinical Pathological Observations
Lawrence A. Yannuzzi, MD
8:30  Update from CAM: A Proposed Classification System for Atrophy
Srinivas R. Sadda, MD
8:40  Using AMD Geographic Atrophy Area as a Clinical Trial Primary Outcome Variable
Frederick L. Ferris, III, MD
8:50  Mechanisms of Low Luminance Vision Loss in AMD
Karl G. Csaky, MD, PhD
9:00  Computational Approaches to Modeling Compromise in the Choroidal Circulation
Philip Luthert, MB BS
9:10  Choriocapillaris Death is an Early Event in Neovascular AMD
Gerard A. Lutty, PhD

SESSION II: OCT Angiographic Imaging
Moderator: Carmen A. Puliafito, MD, MBA

9:20  The Role of the Choriocapillaris in Non-Exudative AMD: An OCT Angiography Based Evaluation
Nadia Waheed, MD
9:30  SS-OCT Angiographic Imaging of the Choriocapillaris in AMD
Fang Zheng, MD
9:40  VISTA – Making OCTA Quantifiable
Jay S. Duker, MD
9:50  OCT Angiographic Prevalence and Natural History of Non-Exudative Neovascular AMD
Joao Rafael De Oliveira Dias, MD
10:00  SD-OCTA vs. SS-OCTA Imaging of CNV in AMD
Philip J. Rosenfeld, MD, PhD
10:10  Biomarkers of Neovascular Activity Using OCT Angiography
David Sarraf, MD
### SESSION III: Emerging Therapies

*Moderator: Philip J. Rosenfeld, MD, PhD*

<table>
<thead>
<tr>
<th>Time</th>
<th>Topic</th>
<th>Presenter</th>
</tr>
</thead>
<tbody>
<tr>
<td>10:20</td>
<td>Top Innovations in Retina – A VC’s Perspective</td>
<td>Emmett T. Cunningham, Jr., MD, PhD, MPH</td>
</tr>
<tr>
<td>10:30</td>
<td>Lipids as Therapeutic Targets in Dry AMD</td>
<td>Rajendra S. Apte, MD, PhD</td>
</tr>
<tr>
<td>10:40</td>
<td>Macrophage Polarization as Therapeutic Target in Dry AMD</td>
<td>Shelley Boyd, DABO, MD, FRCS(C), BSc</td>
</tr>
<tr>
<td>10:50</td>
<td>Update of Elamipretide (MTP-131) for Dry AMD</td>
<td>Scott W. Cousins, MD</td>
</tr>
<tr>
<td>11:00</td>
<td>Complement C3 Inhibition in AMD</td>
<td>Cedric G. Francois, MD, PhD</td>
</tr>
<tr>
<td>11:10</td>
<td>Development of a MAC Inhibitor for Dry AMD Using a Gene Therapy Approach</td>
<td>Elias Reichel, MD</td>
</tr>
<tr>
<td>11:20</td>
<td>Intravitreal Approaches to Retinal Gene Therapy: Results from Second Generation Vectors and Molecules</td>
<td>David M. Brown, MD, FACS</td>
</tr>
<tr>
<td>11:30</td>
<td>Technical Aspects of Gene Delivery in AMD by Sub Retinal Surgical Approaches: Imaging Results and the Efficacy Impact of Location of Injection and Choice of Agent</td>
<td>Szilárd Kiss, MD</td>
</tr>
<tr>
<td>11:40</td>
<td>A Sustained Release Liposomal Delivery System</td>
<td>Peter K. Kaiser, MD</td>
</tr>
</tbody>
</table>

### SESSION IV: Neovascular Age-Related Macular Degeneration

*Moderator: Zohar Yehoshua, MD, MHA*

<table>
<thead>
<tr>
<th>Time</th>
<th>Topic</th>
<th>Presenter</th>
</tr>
</thead>
<tbody>
<tr>
<td>11:50</td>
<td>Incidence of New Choroidal Neovascularization in Fellow Eyes of Patients Treated in the VIEW Trials</td>
<td>K. Bailey Freund, MD</td>
</tr>
<tr>
<td>12:00</td>
<td>Long Term Outcomes in Patients Treated for Neovascular AMD</td>
<td>Daniel F. Martin, MD</td>
</tr>
<tr>
<td>12:10</td>
<td>Progression Rate of RPE Loss in Patients with Neovascular AMD Treated with Different VEGF Inhibitors</td>
<td>Stephan Michels, MD, MBA</td>
</tr>
<tr>
<td>12:20</td>
<td>Two Year Results from the VIEW 1&amp;2 Extension: RANGE Trial</td>
<td>W. Lloyd Clark, MD</td>
</tr>
<tr>
<td>12:30</td>
<td>Brolucizumab vs. Aflibercept Treatment for Neovascular AMD</td>
<td>Lawrence J. Singerman, MD, FACS, FICS</td>
</tr>
<tr>
<td>12:40</td>
<td>Risk Factors for Fibrosis in the Anti-VEGF Era</td>
<td>Usha Chakravarthy, MD</td>
</tr>
</tbody>
</table>
SESSION V: Neovascular AMD: Combination Therapies
Moderator: Carmen A. Puliafito, MD, MBA

1:40 Anti-PDGF Therapy for Neovascular AMD
Pravin U. Dugel, MD

1:50 Morphology-Visual Acuity Correlations after anti-VEGF/anti-PDGF Therapy for Neovascular AMD
Glenn J. Jaffe, MD

2:00 Combination Therapy with Aflibercept for the Treatment of Neovascular AMD
Jeffrey S. Heier, MD

2:10 Icon-1 in the Treatment of Neovascular AMD: Phase 2a Study Results
Carl D. Regillo, MD, FACS

2:20 Topical Squalamine for Neovascular AMD: An Update
Jason S. Slakter, MD

SESSION VI: Stem Cells and Retinal Degenerations
Moderator: Wen-Hsiang Lee, MD, PhD

2:30 Patient-Funded Stem Cell Therapies: A Report of Three Cases and Their Clinical and Regulatory Context
Thomas A. Albini, MD

2:40 Long-Term Outcomes of hESC-Derived RPE Cell Transplantation in Atrophic AMD and Stargardt Disease
Ninel Z. Gregori, MD

2:50 Stem Cell Derived RPE Transplantation - An Update of the London Project
Lyndon Da Cruz, MD

3:00 Embryonic Stem cell-Derived RPE: The California Project, A Phase 1/2a Clinical Trial
David R. Hinton, PhD

3:10 Subretinal Transplantation of RPE Cells Derived from Human Embryonic Stem Cells in Patients with Advanced Dry AMD: Observations from the Hadassah Phase I/IIa Clinical Trial
Eyal Banin, MD, PhD

3:20 Autologous iPSC-RPE Cell Therapy for AMD
Kapil Bharti, PhD

3:30 Toward More Precise Sub Retinal Therapeutic Delivery: New Techniques and Instrumentation
Allen C. Ho, MD

3:40 Clinical Translation of Retinal Progenitors Cells for RP: The jCyte Experience
Henry J. Klassen, MD, PhD

3:50 Update on Clinical Trials for Retinal Degenerations
Byron L. Lam, MD
SESSION VII: Diabetic Retinopathy  
Moderator: Harry W. Flynn, Jr., MD

4:00  
DRCR.net Update  
Harry W. Flynn, Jr., MD

4:10  
Slurry Kenalog: A Lower Cost, Quick and Easy Alternative for Long-Term Intraocular Steroid Delivery  
Susan Malinowski, MD

4:20  
Update on Aflibercept Pharmacokinetics and Treatment of Diabetic Macular Edema  
Diana V. Do, MD

4:30  
Ziv-Aflibercept in Diabetic Macular Edema  
Michel E. Farah, MD

4:40  
ENDURANCE Extension Study Following the VISTA DME Study  
Charles C. Wykoff, MD, PhD

4:50  
Peripheral and Macular Retinal Vascular Perfusion and Leakage Dynamics in Diabetic Macular Edema and Retinal Venous Occlusions During Intravitreal Aflibercept Injection (IAI) Treatment for Retinal Edema: PERMEATE Study  
Justis P. Ehlers, MD

5:00  
Anti-Integrin Treatment for Diabetic Edema  
David S. Boyer, MD

5:10  
Impact of Cataract Surgery on Visual Acuity and OCT in DME Patients Undergoing Anti-VEGF Therapy  
Andrew A. Moshfeghi, MD, MBA

SESSION VIII: Uveitis and Retinal Vascular Diseases  
Moderator: Jaclyn L. Kovack, MD

5:20  
Intravitreal Sirolimus for Non-Infectious Uveitis: Primary Outcomes of the Phase3 SAKURA 2 Study  
Quan D. Nguyen, MD, MSc

5:30  
Suprachoroidal Triamcinolone Acetonide for Retinal Vein Occlusion: Results of the Tanzanite Trial  
Peter A. Campochiaro, MD

5:40  
MacTel Project Update  
Martin Friedlander, MD, PhD

5:50  
Near-Term Safety of Bevacizumab in Treatment of Retinopathy of Prematurity  
Darius M. Moshfeghi, MD

6:00  
Advances in Mobile Device Enabled Retinal Fundus Photography for Clinical Research and Public Health Screening  
Mark S. Blumenkranz, MD

6:10  
Adjourn/Cocktail Reception
DATE
Saturday, February 11, 2017: 7:55 am to 6:10 pm

LOCATION
Mandarin Oriental Miami, Miami, Florida
500 Brickell Key Drive, Miami, FL 33131
Reservations: (800) 526-6566, Direct: (305) 913-8288

Mandarin Oriental Miami is one of America’s finest hotels and recently voted Best Urban Hotel by Miami Herald’s Readers Choice South Florida’s Finest survey-Best of South Florida. Ideally located on prestigious Brickell Key, its deluxe, waterfront location perfectly befits the opulence you’ll find within. The rooms are luxurious, the award-winning restaurants are some of the finest in Miami and the spa is one of the most beautiful in the world. The hotel’s extensive leisure facilities make it the perfect choice for a conference or a holiday in Miami.

HOTEL RESERVATIONS
For hotel information and reservations, please call 305-913-8288 or 800-526-6566.

The special hotel rate for conference attendees is $409 per night for single or double plus tax. The Mandarin Oriental will extend the special group rate for three days prior and three days after the main program dates, subject to availability. Check-in time is 3:00 pm; Check-out time is 12:00 noon.

We suggest you make your hotel reservations as soon as possible as the winter months are the height of South Florida’s tourist season. Bascom Palmer’s preferred room rate will be released after January 11, 2017. Reservations and deposits received after that time are subject to current rates and availability. Please contact the Mandarin Oriental Miami for hotel cancellation policies. For additional information visit: www.mandarinoriental.com/miami

CONFERENCE FEES
Registration rate is $475.
Conference fees include course materials, opening reception, continental breakfast, lunch and refreshment breaks.

CANCELLATION POLICY
Conference tuition, less a $50 cancellation fee, is refundable if notice is received by January 27, 2017. No refunds shall be considered after January 27, 2017 or after sixty (60) days following payment.
ACCREDITATION:
The University of Miami Leonard M. Miller School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

CREDIT DESIGNATION:
The University of Miami Leonard M. Miller School of Medicine designates this live activity for a maximum of 9.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

DISCLOSURE AND CONFLICT OF INTEREST RESOLUTION:
All conflicts of interest of any individual(s) in a position to control the content of this CME activity will be identified and resolved prior to this educational activity being provided. Disclosure about provider and faculty relationships, or the lack thereof, will be provided to learners.

SERVICES FOR THE DISABLED
If special arrangements are required for an individual with a disability to attend this conference, please contact Karen Davila at (305) 326-6110 on or before January 27, 2017.

REGISTRATION
Space is limited. Please register early.

To register by internet: Please visit: http://bascompalmer.org/cme/angiogenesis/registration

To register by mail: Please complete the registration form and return with your check or credit card payment to:
Bascom Palmer Eye Institute
Department of Continuing Medical Education
1400 NW 10th Ave., Suite 508
Miami, FL 33136 (Att: Karen Davila)

To register by fax: Please complete the registration form and return with your credit card payment to (305) 326-6518.

For more information contact:
Bascom Palmer Eye Institute
Department of Continuing Medical Education at
(305) 326-6110 / Email: bascompalmercme@miami.edu
Bascom Palmer Eye Institute
Angiogenesis, Exudation, and Degeneration 2017

Saturday, February 11, 2017
Registration is limited, so please register early.

REGISTRATION: $475

Enclosed is my check made payable to Bascom Palmer Eye Institute–Angiogenesis 2017

Please bill my credit card:

☐ Mastercard  ☐ Visa  ☐ American Express

Name on card

Online: http://bascompalmer.org/cme/angiogenesis/registration

By fax: Please complete this registration form with your credit card payment and fax to (305) 326-6518. By mail: Please complete this registration form and return with your check or credit card payment to:

Bascom Palmer Eye Institute
Continuing Medical Education Department
1400 NW 10th Ave., Suite 508
Miami, FL 33136
(Attn: Karen Davila)